FDA Approves Lilly's Inluriyo-Verzenio Combo for ESR1-Mutant Breast Cancer
LLY sits 61% above its 52-week low of $712.05.
Summary
The FDA granted full approval to Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. This is the second approval for Inluriyo in under a year, expanding its label from monotherapy to combination use. In the Phase 3 EMBER-3 trial, the combination doubled median progression-free survival versus Inluriyo alone (11.1 vs 5.5 months, HR=0.53). The approval strengthens Lilly's oncology franchise and provides a new standard-of-care option in a patient population with limited alternatives. The drug is now available in the U.S., and the company is also running the large adjuvant EMBER-4 trial with results expected in 2027.
At the time of this announcement, LLY was trading at $1,144.63 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.